2 / 30
REGOVAL 80, 160 mg.
Each tablet contains 80, 160 mg valsartan respectively. S3 A43/7.1.3/0548, 0549. For full prescribing information, refer to the professional information approved by SAHPRA, October 2019.
REGOVAL
CO 80/12,5, 160/12,5, 160/25 mg.
Each tablet contains 80, 160, 160 mg valsartan respectively and 12,5, 12,5, 25 mg hydrochlorothiazide respectively. S3 A44/7.1.3/0018, 0019, 0020. For full prescribing information, refer
to the professional information approved by SAHPRA, September 2019.
1)
Williams B,
et al.
2018 ESC/ESH guidelines for the management of arterial hypertension.
Journal of Hypertension
2018;36:1953-2041.
2)
Black HR,
et al.
Valsartan, more than a decade of experience.
Drugs
2009;69(17):2393-2414.
RGLA651/07/2020.
A Lupin Group Company
For further product information contact
PHARMA DYNAMICS
P O Box 30958 Tokai Cape Town 7966
Fax
+27 21 701 5898
CUSTOMER CARE LINE
0860 PHARMA (742 762) / +27 21 707 7000
www.pharmadynamics.co.zaELEVATED BP IS A RISK FACTOR FOR:
1
• myocardial infarction
• heart failure
• stroke and renal disease
VALSARTAN HAS:
2
• proven e cacy in a broad range of patients
• a placebo-like side e ect profile for common adverse events
CONVENIENTLY PACKED IN
30
TABLETS.
REDUCE THE RIPPLE EFFECT
NEW
INTRODUCING OUR
VALSARTAN
RANGE